UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Blood, 2020-09, Vol.136 (12), p.1433-1441

2020

Volltextzugriff (PDF)

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

The Lancet (British edition), 2009-02, Vol.373 (9663), p.567-574

2009

Volltextzugriff (PDF)

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Journal of clinical oncology, 2018-07, Vol.36 (20), p.2017-2023

2018

Volltextzugriff (PDF)

Hepatic drug targeting: Phase I evaluation of polymer-bound Doxorubicin

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1668-1676

2002

Volltextzugriff (PDF)

Essential oncology nursing care along the cancer continuum

The lancet oncology, 2020-12, Vol.21 (12), p.e555-e563

2020

Volltextzugriff (PDF)

Uncertainty upon uncertainty: supportive Care for Cancer and COVID-19

Supportive care in cancer, 2020-09, Vol.28 (9), p.4001-4004

2020

Volltextzugriff (PDF)

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

Journal of thrombosis and haemostasis, 2020-04, Vol.18 (4), p.905-915

2020

Volltextzugriff (PDF)

Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta‐analysis

Journal of thrombosis and haemostasis, 2021-10, Vol.19 (10), p.2468-2479

2021

Volltextzugriff (PDF)

The UK's contribution to cancer control in low-income and middle-income countries

The lancet oncology, 2021-09, Vol.22 (9), p.e410-e418

2021

Volltextzugriff (PDF)

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting

The oncologist (Dayton, Ohio), 2018-07, Vol.23 (7), p.822-839

2018

Volltextzugriff (PDF)

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

Current medical research and opinion, 2023-03, Vol.39 (3), p.483-495

2023

Volltextzugriff (PDF)

Building capacity for sustainable research programmes for cancer in Africa

Nature reviews. Clinical oncology, 2014-05, Vol.11 (5), p.251-259

2014

Volltextzugriff (PDF)

Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review

Curēus (Palo Alto, CA), 2022-03

2022

Volltextzugriff (PDF)

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

Supportive care in cancer, 2014-10, Vol.22 (10), p.2677-2685

2014

Volltextzugriff (PDF)

Cancer Patients’ Experiences and Understanding of Venous Thromboembolism

Al-Kindy College medical journal, 2021-12, Vol.17 (3), p.128-134

2021

Volltextzugriff (PDF)

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1668-1676

Seymour, L. W.

2002

Volltextzugriff (PDF)

Targeted therapies Bevacizumab-has it reached its final resting place?

Nature reviews. Clinical oncology, 2011-04, Vol.8 (4), p.195-196

2011

Volltextzugriff (PDF)

Bevacizumab—has it reached its final resting place?

Nature reviews. Clinical oncology, 2011-04, Vol.8 (4), p.195-196

2011

Volltextzugriff (PDF)

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Journal of controlled release, 1999-02, Vol.57 (3), p.281-290

1999

Volltextzugriff (PDF)

Abstract P5-08-04: Mammo-50: Mammographic surveillance in early breast cancer patients aged over 50 years – patient reported outcomes 3 years post diagnosis

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.P5-P5-08-04

2023

Volltextzugriff (PDF)

Chemotherapy side-effect management using mobile phones

2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2008-01, Vol.2008, p.5152-5155

2008

Volltextzugriff (PDF)

Venous Thromboembolism Rate in Patients with Bladder Cancer According to the Type of Treatment: A systematic review

Journal of Clinical Oncology and Therapeutics, 2021, Vol.3 (2)

2021

Volltextzugriff (PDF)

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP) : an open-label randomised trial. Commentary

The Lancet (British edition), 2009, Vol.373 (9663)

2009

Volltextzugriff (PDF)

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients

Blood, 2005-11, Vol.106 (11), p.909-909

2005

Volltextzugriff (PDF)

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Clinical pharmacokinetics, 1999-06, Vol.36 (6), p.391-398

1999

Volltextzugriff (PDF)

1 – 25 von 184

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(150)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Hepatic drug targeting: Phase I evaluation of polymer-bound Doxorubicin

Essential oncology nursing care along the cancer continuum

Uncertainty upon uncertainty: supportive Care for Cancer and COVID-19

Treatment of cancer‐associated venous thromboembolism: 12‐month outcomes of the placebo versus rivaroxaban randomization of the SELECT‐D Trial (SELECT‐D: 12m)

Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta‐analysis

The UK's contribution to cancer control in low-income and middle-income countries

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

Building capacity for sustainable research programmes for cancer in Africa

Venous Thromboembolism Rate in Patients With Bladder Cancer According to the Type of Treatment: A Systematic Review

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring — supporting patients in their homes

Cancer Patients’ Experiences and Understanding of Venous Thromboembolism

Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin

Targeted therapies Bevacizumab-has it reached its final resting place?

Bevacizumab—has it reached its final resting place?

Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine

Abstract P5-08-04: Mammo-50: Mammographic surveillance in early breast cancer patients aged over 50 years – patient reported outcomes 3 years post diagnosis

Chemotherapy side-effect management using mobile phones

Venous Thromboembolism Rate in Patients with Bladder Cancer According to the Type of Treatment: A systematic review

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP) : an open-label randomised trial. Commentary

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Suchergebnisse filtern